Exon skipping and splice modulation using synthetic antisense oligonucleotides (AONs) are therapeutic approaches to delay or arrest the progression of genetic diseases. AON-mediated exon skipping modifies pre-mRNA splicing to correct the reading frame of genes responsible for disease and modulate a protein structure, providing therapeutic benefits. Studied for over two decades, exon skipping AONs have received conditional marketing authorization for Duchenne muscular dystrophy (DMD). The US Food and Drug Administration (FDA) has granted accelerated approval for four AONs to skip a single DMD exon for treating patients with DMD: eteplirsen for exon 51 skipping, golodirsen and viltolarsen for exon 53 skipping, and casimersen for exon 45 skipping. Various preclinical and clinical trials are underway with AONs targeting other exons and ones loading bioconjugates, such as cell-penetrating peptides and antibodies to enhance the exon skipping ability. Besides AONs targeting pre-mRNA, genomic DNA target exon skipping using Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) technology, which holds promise in current preclinical trials for DMD. In hopes of achieving clinical success parallel to DMD, exon skipping and splice modulation are studied in other muscular dystrophies, such as Fukuyama congenital muscular dystrophy (FCMD), dysferlinopathy including limb-girdle muscular dystrophy type 2B (LGMD2B), Miyoshi myopathy (MM), and distal anterior compartment myopathy (DMAT), myotonic dystrophy, and merosin-deficient congenital muscular dystrophy type 1A (MDC1A). Splice-modulating AONs have also been extensively tested in other inherited diseases, such as Usher syndrome, dystrophic epidermolysis bullosa (DEB), fibrodysplasia ossificans progressiva (FOP), and allergic diseases. This chapter will introduce the developmental status of exon skipping and splice-modulating therapies for genetic diseases.